Código QR (código de barras bidimensional)

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics

ObjectivesPosterior reversible encephalopathy syndrome (PRES) is a rare but potentially severe complication of VEGF-pathway inhibition. A recent FAERS analysis supported PRES as a probable class effect of angiogenesis inhibitors but found no association with continuous VEGFR affinity, did not formal...

תיאור מלא

שמור ב:
Principais autores: Ji Li, Yan Cheng, Yunzhou Yang
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2026-07-01
סדרה:Frontiers in Pharmacology
נושאים:
disproportionality analysis
FAERS
fruquintinib
pharmacovigilance
posterior reversible encephalopathy syndrome
ramucirumab
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fphar.2026.1887454/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים